Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation - Wikidata - awgldk - TriplyDB

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

http://www.wikidata.org/entity/Q28076600

about

Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries.Treatment of severe drug reactions by hemodialysis.The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China.Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity.Allergy to chlorpromazine and valproic acid following carbamazepine hypersensitivity in a patient with an HLA-B*4601 allele.Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.

P2860

Q39359391-840CD76B-63FA-4B42-B546-5E5AD9B8463E Q47600128-767B8174-FC02-4871-8C62-10A1BEEFCBD3 Q52614370-AA5DA704-DA5E-440F-B888-6F9A4D69AFD4 Q52684197-C6391148-56B9-4529-9618-26992303EF27 Q52719665-36B7E6B8-19B8-46DF-92C1-82460A9D6F1A Q55124503-5D02A567-B43D-42F6-95DC-D8C2F712AF06 Q55324381-21420B7D-4054-434D-AD58-8A3D8CFA8EC8

P2860

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

http://www.wikidata.org/entity/Q28076600

description

2016 nî lūn-bûn

@nan

2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@ast

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@en

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@nl

type

label

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@ast

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@en

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@nl

prefLabel

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@ast

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@en

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@nl

P1433

Q28076600-4D436E84-8695-4ED8-8F4D-2F2190CD1290

P1476

Q28076600-5DD65F2C-8EFB-4179-BCC0-90AF3D4BD29E

P2093

Q28076600-6962EAAA-508B-48A2-8191-017CD1AB347C

Q28076600-8556457F-D89C-4AAB-A3AD-0066A9F0F744

Q28076600-AA3970B1-90BA-40D4-8965-F264A85E8309

Q28076600-C12C1853-99F8-4CA1-A332-4A9051248749

P275

Q28076600-A6D33838-279B-4AC5-888D-89D935646212

P2860

Q28076600-00199E87-E0DB-463F-8596-E140DE4C13D6

Q28076600-0080D229-7379-48F9-A7D3-9EE409F3B6E9

Q28076600-01FBA238-6163-49A5-9923-52943543B110

Q28076600-054046A0-88AD-49C4-A1D6-C9FAFD798C55

Q28076600-0A3668D0-A9F5-46FE-80C0-A08B18576E58

Q28076600-0C81E4A6-CAF3-4AC5-B8CD-7EE4736E41DC

Q28076600-11329F29-EF3C-455E-9C51-063177861E45

Q28076600-1E529BE9-A848-49AB-BCA8-95A86D9B7B63

Q28076600-20CFC63A-7887-40AB-96DD-4A5066D8A9CC

Q28076600-23D60F46-EBEA-40AF-8D5B-22819CC4CA02

P31

Q28076600-A6A2E2F2-3434-4104-9487-1F74B8D75279

Q28076600-E832DF0A-8C42-4DC7-98B4-F4EDB07BB004

P356

Q28076600-17840E6D-AFC8-4835-9E15-0B907CADB911

P407

Q28076600-1CF9C81F-AB9C-4BB5-9A88-88AC40C449A4

P433

Q28076600-BE7C988F-9E94-481A-9830-6807585E74C7

P478

Q28076600-F77E2B2A-D1AD-4E95-BC3C-9247CEE0EB86

P50

Q28076600-E0C1E39D-4A65-4292-A2A6-DD05CB4B7ABE

P5008

Q28076600-56A61953-DE8C-4B86-AC37-8C682DCA309D

P577

Q28076600-B18FBB59-6042-4CE9-A9D2-0CD13138DAA2

P698

Q28076600-25A7AAFC-ACCB-45D1-A860-EF9E7EAD9AE4

P921

Q28076600-34676EFC-2BF0-4CEA-85E4-431E7FBB5034

Q28076600-710F4FEA-8B98-458A-ABED-F22B3A65A9F4

Q28076600-F0967530-338B-48D0-BD9F-B03960CFDBA7

P932

Q28076600-4B6589DE-D506-40C8-92BC-951C561C3C86

P356

P1433

International Journal of Molecular Sciences

P1476

Severe Cutaneous Adverse React ...... rch to Clinical Implementation

@en

P2093

Ro-Lan Dao

http://www.w3.org/2001/XMLSchema#string

Shih-Chi Su

http://www.w3.org/2001/XMLSchema#string

Wen-Hung Chung

http://www.w3.org/2001/XMLSchema#string

Wen-Lang Fan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

Drug induced exfoliative dermatitis: state of the art

T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance

Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire

Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

Medical genetics: a marker for Stevens-Johnson syndrome

Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population

A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

P31

scholarly article

P356

10.3390/IJMS17111890

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2016-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27854302

http://www.w3.org/2001/XMLSchema#string

P921

Stevens-Johnson syndrome

pharmacogenomics

pharmacogenetics

P932

5133889

http://www.w3.org/2001/XMLSchema#string